drugset / Trial / NCT06018467
Senolytics to Improve Osteoporosis Therapy
Phase 2
Active not recruiting
120 enrolled
Odense University Hospital
Odense Patient Data Explorative Network · collabThe Novo Nordisk Foundation Center for Basic Metabolic Research · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This randomised clinical trial aims to study osteoporosis as a disease of accelerated skeletal aging caused by the accumulation of senescent cells within the skeleton and investigate the effects and safety of senolytics and antioxidant therapy on bone.
Timeline
- Start
- 2023-09-06
- Primary completion
- 2026-04-30
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |